Contributors
Ghulam Abbas, Anita P. Courcoulas(University of Pittsburgh Medical Center), Mieke Cannie(KU Leuven), Michael Bousamra(University of Louisville), Mario Brandolino, Ayesha S. Bryant(University of Alabama at Birmingham), Mark S. Allen(Institut für Sozialforschung und Sozialwirtschaft), Sanjeev Bhalla(Mallinckrodt (United States)), Raúl Burgos(Pontificia Universidad Católica de Valparaíso), W. Fred Bennett, Michael Andritsos, Robert J. Cerfolio(NYU Langone Health), David J. Adelstein(Cleveland Clinic), Simon Ashiku, Nasser K. Altorki(Cornell University), Jacques E. Chelly, Brendan J. Boland, Gilles Beauchamp, Marco Alifano(Assistance Publique – Hôpitaux de Paris), Yves Bergeron(Université du Québec en Abitibi-Témiscamingue), Ross M. Bremner(Creighton University), Evaristo Castedo, Joshua H. Burack, Carl E. Bredenberg(State University of New York), Stephen D. Cassivi(Mayo Clinic), Javier H. Campos, Mark E. Baker(Cleveland Clinic), Jean S. Bussières(Institut universitaire de cardiologie et de pneumologie de Québec), Farzaneh Banki(Memorial Hermann), Ibrahim B. Cetindag, Nancy L. Bartlett(Washington University in St. Louis), Priscilla Chiu(University of Toronto), Costas Bizekis, Majit S. Bains, Clemens Aigner(Comprehensive Cancer Center Vienna), Mary P. Bronner(University of Utah), Joel D. Cooper(Hospital of the University of Pennsylvania), Rafael S. Andrade, Ricardo Bello, Alan G. Casson, Michel Bergeron, R. Brannon Claytor, Mauricio Arruda(Cleveland Research (United States)), Richard J. Battafarano(Johns Hopkins University), Carl L. Backer(Cincinnati Children's Hospital Medical Center), Neil A. Christie(University of Pittsburgh), Jeffrey D. Bradley(Hospital of the University of Pennsylvania), Ahmad S. Ashrafi, Andy T.A. Chung
Cited by 0
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k